Annual Report on 2008 External Quality Assessment in Therapeutic Drug Monitoring and Drug of Abuse in Korea (2008).
- Author:
Jeong Ho KIM
1
;
Woonhyoung LEE
;
Byung Kwang KIM
;
Soo Youn LEE
;
Sail CHUN
;
Gye Cheol KWON
;
Yeomin YOON
;
Dong Hoon SHIN
;
Kyung Eun SONG
;
Seon Mi SONG
;
Soon Pal SUH
;
Jin Q KIM
Author Information
1. Therapeutic Drug Monitoring Subcommittee, The Korean Association of Quality Assurance for Clinical Laboratory, Seoul, Korea. jeongho@yuhs.ac
- Publication Type:Review
- Keywords:
Quality assurance;
External quality assessment;
Therapeutic drug monitoring
- MeSH:
Acetaminophen;
Amikacin;
Carbamazepine;
Cyclosporine;
Digoxin;
Drug Monitoring;
Gentamicins;
Korea;
Lithium;
Methotrexate;
Phenobarbital;
Phenytoin;
Primidone;
Tacrolimus;
Theophylline;
Tobramycin;
Valproic Acid;
Vancomycin
- From:Journal of Laboratory Medicine and Quality Assurance
2009;31(1):125-141
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Two trials of external quality assessment for Therapeutic Drug Monitoring (TDM) subcommittee of Korean Association of Quality Assurance for Clinical Laboratory (KAQACL) were performed in 2008. The number of participating laboratories were 114, which is similar with that of the previous year. Average response rates were 97.8% in both trials slightly lower than that of the previous year. Two kinds of control materials were requested to be tested in each trial so that each laboratory could know the possible systematic error. The average drug item was 6.3 per laboratory, which was decreased slightly from 6.8 in recent 5 years, and the maximum was 18 items. The most common test items were valproic acid, digoxin, carbamazepine, theophylline, phenytoin, and phenobarbital which were peformed in more than 52.1% of participating laboratories, followed by cyclosporine, vancomycin, tacrolimus, lithium, methotrexate, amikacin, tobramycin, gentamycin, acetaminophen, salicylate, free phenytoin, primidone, and amitryptyline. The widely used TDM analyzers were Abbott TDx/TDxFLx (35.3%), followed by Abbott AxSym (26.5%) and Roche Cobas Integra (17.3%), Abbott IMx (3.3%), and Siemens Viva E (3.0%). The inter-laboratory coefficients of variations showed similar tendency comparing with those of the previous years. The number of participating laboratories for drug of abuse tests were 17, which is similar to that of the previous year. Average drug item were 3.7 for the 1st trial. We found the relatively good performance as we got the correct answers for all laboratories except 2 laboratories. In conclusion, the TDM external quality assessment of 2008 showed grossly similar pattern comparing with that of previous year.
